Incidentally found pulmonary embolism: What's the clinician to do?

Hematology (United States)

Volumn 2015, Issue 1, 2015, Pages 197-201

  O'Connell, Casey ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; DEEP VEIN THROMBOSIS; HEMOSTASIS; HUMAN; INCIDENTAL FINDING; LUNG BLOOD VESSEL; LUNG EMBOLISM; MORTALITY; RISK FACTOR; VENOUS THROMBOEMBOLISM; ALGORITHM; COMPLICATION; NEOPLASMS; PROGNOSIS; PULMONARY EMBOLISM; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTICOAGULANT AGENT;

ALGORITHMS; ANTICOAGULANTS; BLOOD COAGULATION; HEMORRHAGE; HUMANS; INCIDENTAL FINDINGS; NEOPLASMS; PROGNOSIS; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 85010976816     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2015.1.197     Document Type: Article

References (26)

1. Patel S, Kazerooni EA, Cascade PN. Pulmonary embolism: optimization of small pulmonary artery visualization at multi-detector row CT. Radiology 2003;227(2):455-460.
2. Pena E, Kimpton M, Dennie C, Peterson R, Le Gal G, Carrier M. Difference in interpretation of computed tomography pulmonary angiography diagnosis of subsegmental thrombosis in patients with suspected pulmonary embolism. J Thromb Haemost. 2012;10(3):496-498.
3. Dentali F, Ageno W, Becattini C, et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res. 2010;125(6):518-522.
4. O'Connell CL, Boswell WD, Duddalwar V, et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 2006;24(30):4928-4932.
5. Abdel-Razeq HN, Mansour AH, Ismael YM. Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome-a comprehensive cancer center experience. Vasc Health Risk Manag. 2011;7:153-158.
6. Shteinberg M, Segal-Trabelsy M, Adir Y, et al. Clinical characteristics and outcomes of patients with clinically unsuspected pulmonary embolism versus patients with clinical suspected pulmonary embolism. Respiration. 2012;84(6):492-500.
7. O'Connell C, Razavi P, Liebman H. Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism. J Clin Oncol. 2011;29(31):4208-4209.
8. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(Suppl):e419S-e494S.
9. Donato AA, Khoche S, Santora J, Wagner B. Clinical outcomes in patients with isolated subsegmental pulmonary emboli diagnosed by multidetector CT pulmonary angiography. Thromb Res. 2010;126(4): e266-e270.
10. Den Exter PL, Van Es J, Klok FA, et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood. 2013;122(7):1144-1149.
11. Carrier M, Righini M, Wells PS, et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost. 2010;8(8):1716-1722.
12. Den Exter PL, Van Roosmalen JG, Van Den Hoven P, et al. Physicians' management approach to an incidental pulmonary embolism: an international survey. J Thomb Haemost. 2013;11:208-213.
13. Vedovati MC, Germini F, Agnelli G, Becattini C. Prognostic role of embolic burden assessed at computed tomography angiography in patients with acute pulmonary embolism: systemic review and metaanalysis. J Thomb Haemost. 2013;11(12):2092-2102.
14. O'Connell CL, Razavi P, Ghalichi M, et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost. 2011;9(2):305-311.
15. Righini M, Le Gal G, De Lucia S, et al. Clinical usefulness of D-dimer testing in cancer patients with suspected pulmonary embolism. Thromb Haemost. 2006;95(4):715-719.
16. Geersing GJ, Zuithoff NP, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ. 2014;348:g1340.
17. Di Nisio M, Lee AYY, Carrier M, et al. Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. J Thomb Haemost. 2015;13:880-883.
18. Wells PS, Ginsberg JS, Anderson DR, et al. Utility of ultrasound imaging of the lower extremities in the diagnostic approach in patients with suspected pulmonary embolism. J Intern Med. 2001;250(3):262-264.
19. Palla A, Rossi G, Falaschi F, Marconi L, Pistolesi M, Prandoni P. Is incidentally detected pulmonary embolism in cancer patients less severe? A case-control study. Cancer Invest. 2012;30(2):131-134.
20. Tomkowski WZ, Davidson BL, Winiewska J, et al. Accuracy of compression ultrasound in screening for deep venous thrombosis in acutely ill medical patients. Thromb Haemost. 2007;97(2):191-194.
21. Burns KE, Iacono AT. Incidence of clinically unsuspected pulmonary embolism in mechanically ventilated lung transplant recipients. Transplantation. 2003;76(6):964-968.
22. Burns KE, Iacono AT. Pulmonary embolism on postmortem examination: an under-recognized complication in lung-transplant recipients? Transplantation. 2004;77(5):692-698.
23. Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013;31(17):2189-2204.
24. den Exter PL, Hooijer J, Dekkers OM, et al. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 2011;29(17):2405-2409.
25. Kooiman J, van Hagen N, Iglesias Del Sol A, et al. The HAS-BLED Score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment. PLoS One. 2015:10(4):e0122520.
26. Francis C, Kessler C, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to twelve months. The DALTECAN Study. J Thromb Haemost. 2015;13(6):1028-1035.